TY - JOUR
T1 - Prognostic significance of circulating plasma cells by multi-parametric flow cytometry in light chain amyloidosis
AU - Sidana, Surbhi
AU - Tandon, Nidhi
AU - Dispenzieri, Angela
AU - Gertz, Morie A.
AU - Dingli, David
AU - Jevremovic, Dragan
AU - Morice, William G.
AU - Kapoor, Prashant
AU - Kourelis, Taxiarchis V.
AU - Lacy, Martha Q.
AU - Hayman, Suzanne R.
AU - Buadi, Francis K.
AU - Leung, Nelson
AU - Go, Ronald S.
AU - Lin, Yi
AU - Russell, Stephen J.
AU - Lust, John A.
AU - Zeldenrust, Steven R.
AU - Warsame, Rahma
AU - Hwa, Yi L.
AU - Hobbs, Miriam
AU - Fonder, Amie
AU - Kyle, Robert A.
AU - Rajkumar, S. Vincent
AU - Kumar, Shaji K.
AU - Gonsalves, Wilson I.
N1 - Funding Information:
Acknowledgements The Mayo Clinic Hematological Malignancies Program and in part by grants K23CA218742, CA107476, CA168762, and CA186781 from the National Cancer Institute, Rockville, MD, USA. It is also supported in part by the Jabbs Foundation, Birmingham, United Kingdom, the Henry J. Predolin Foundation, USA, and the Marion Schwartz Foundation for Multiple Myeloma.
Funding Information:
The Mayo Clinic Hematological Malignancies Program and in part by grants K23CA218742, CA107476, CA168762, and CA186781 from the National Cancer Institute, Rockville, MD, USA. It is also supported in part by the Jabbs Foundation, Birmingham, United Kingdom, the Henry J. Predolin Foundation, USA, and the Marion Schwartz Foundation for Multiple Myeloma.
Publisher Copyright:
© 2018 Macmillan Publishers Limited, part of Springer Nature.
PY - 2018/6/1
Y1 - 2018/6/1
N2 - We evaluated the prognostic impact of clonal circulating plasma cells (cPCs) detected by six-color multi-parametric flow cytometry (MFC) in light chain (AL) amyloidosis at diagnosis. Of the 154 patients who underwent MFC, cPCs were detected in 42% (n = 65) patients. Median number of cPCs was 81 per 150,000 events (range: 6-17,844). High bone marrow plasma cell percentage was an independent predictor of presence of cPCs. Presence of cPCs at diagnosis was associated with inferior overall survival (OS) (90 vs. 98 months, p = 0.003) and inferior progression free survival (PFS) (31 vs. 52 months, p = 0.02). Estimated 1, 2 and 5 year OS in the two groups was: 74, 64 and 57 and 89, 87, and 80%, respectively. Estimated PFS at 1, 2, and 5 years was: 69, 56, and 23% and 80, 74, and 37%, respectively. Furthermore, the presence of cPCs at diagnosis was an independent adverse predictor of OS in multivariable analysis. Achieving a very-good partial response, or better, was able to overcome the adverse impact of cPCs at diagnosis. Patients with cPCs at diagnosis may warrant closer monitoring post-treatment, especially if they do not achieve a deep hematologic response.
AB - We evaluated the prognostic impact of clonal circulating plasma cells (cPCs) detected by six-color multi-parametric flow cytometry (MFC) in light chain (AL) amyloidosis at diagnosis. Of the 154 patients who underwent MFC, cPCs were detected in 42% (n = 65) patients. Median number of cPCs was 81 per 150,000 events (range: 6-17,844). High bone marrow plasma cell percentage was an independent predictor of presence of cPCs. Presence of cPCs at diagnosis was associated with inferior overall survival (OS) (90 vs. 98 months, p = 0.003) and inferior progression free survival (PFS) (31 vs. 52 months, p = 0.02). Estimated 1, 2 and 5 year OS in the two groups was: 74, 64 and 57 and 89, 87, and 80%, respectively. Estimated PFS at 1, 2, and 5 years was: 69, 56, and 23% and 80, 74, and 37%, respectively. Furthermore, the presence of cPCs at diagnosis was an independent adverse predictor of OS in multivariable analysis. Achieving a very-good partial response, or better, was able to overcome the adverse impact of cPCs at diagnosis. Patients with cPCs at diagnosis may warrant closer monitoring post-treatment, especially if they do not achieve a deep hematologic response.
UR - http://www.scopus.com/inward/record.url?scp=85042532274&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85042532274&partnerID=8YFLogxK
U2 - 10.1038/s41375-018-0063-7
DO - 10.1038/s41375-018-0063-7
M3 - Article
C2 - 29483709
AN - SCOPUS:85042532274
SN - 0887-6924
VL - 32
SP - 1421
EP - 1426
JO - Leukemia
JF - Leukemia
IS - 6
ER -